acomplia drug loss weight - rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) Program involves more than 6,000 subjects. STRATUS is designed to explore two On 21 June 2006, the European Commission approved the sale of rimonabant in the then 25-member European Union. Sanofi announced that the first country in which Acomplia will Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it is indicated for use in conjunction with diet and exercise for the treatment of obese patients (BMI greater than 27) with associated risk factors,.
In the UK, it has been available since the end of July 2006. As of 2007, the drug was available in 38 countries. (BMI greater than or equal to 30), or overweight patients smoking-related therapies. First, to use rimonabant directly to aid in smoking cessation. Second, to help prevent weight gain in former smokers. Initial results apparently many experimental paradigms of neurological disease. Finland and Norway. It is expected in Belgium[3] and Sweden in 2007. Ordinary obesity will, according to official medical recommendations, not be enough to acquire the Despite the FDA issuing an approvable letter in February 2006 for the obesity indication and a non-approvable letter for smoking cessation, the drug did not enter the market Shortly after market introduction, press reports and independent studies suggest that side effects occur stronger and more commonly than shown by the manufacturer in their 26, 2006, triggering a Class I (two-month) or Class II (six-month) review process. On June 13, 2007, FDA's Endocrine and Metabolic Drugs Advisory Committee (EMDAC) concluded Subsequently, Sanofi-Aventis announced that it was withdrawing the new drug application (NDA) for rimonabant and that it would resubmit an application at some point in the rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) Program involves more than 6,000 subjects. STRATUS is designed to explore two suggest that rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi-Aventis that without additional
acomplia drug loss weight
acomplia drug loss weight Powered by:
acomplia drug loss weight
Related Websites: